Company: PCRX
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050176
Chunk: 83

Company: Pacira BioSciences, Inc.
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 1
Chunk 83
---
 shares from the ESPP (using the treasury stock method), if applicable. Potential common shares associated with convertible senior notes are treated under the if-converted method. Adjustments are made to the diluted net income (loss) per common share calculation as if the Company had converted the convertible senior notes on the first day of each period presented. Adjustments to the numerator are made to add back the interest expense associated with the convertible senior notes on a post-tax basis. Adjustments to the denominator reflect the number of shares assumed to be convertible at the beginning of the period.Potential common shares are excluded from the diluted net income (loss) per common share computation to the extent they would be antidilutive. The following table sets forth the computation of basic and diluted net income (loss) per common share for the three and nine months ended September 30, 2025 and 2024 (in thousands, except per common share amounts):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Numerator:   Net income (loss)$5,432 $(143,466)$5,397 $(115,601)Denominator:   Weighted average common shares outstanding—basic44,038 46,134 45,257 46,269 Computation of diluted securities:   Dilutive effect of stock options37 — 32—    Dilutive effect of RSUs383 — 429 — Dilutive effect of ESPP share options1 — 11 —    Weighted average common shares outstanding—diluted44,459 46,134 45,729 46,269 Net income (loss) per common share:   Basic and diluted net income (loss) per common share$0.12 $(3.11)$0.12 $(2.50)

Pacira BioSciences, Inc.  |  Q3 2025 Form 10-Q  |  28

The following table summarizes the outstanding stock options, RSUs, ESPP share options and convertible senior notes that were excluded from the diluted net income (loss) per common share calculation because the effects of including these potential shares were antidilutive in the periods presented (in thousands):Three Months EndedSeptember 30,Nine Months EndedSeptember 30,2025202420252024Weighted average number of stock options6,488 6,925 6,573 7,305